南美洲和中美洲抗凝逆转药物市场预测至 2027 年 - COVID-19 影响和按产品进行区域分析（凝血酶原复合物浓缩物、维生素 K、鱼精蛋白、氨甲环酸、Idarucizumab 和 AndeXXa）；最终用户（医院药房、零售药房等）
No. of Pages: 124 | Report Code: TIPRE00022215 | Category: Life Sciences
No. of Pages: 124 | Report Code: TIPRE00022215 | Category: Life Sciences
在某些情况下需要抗凝逆转药物来逆转抗凝效果，例如计划外手术、抗凝治疗过量、和不受控制的出血。在静脉血栓栓塞、心房颤动 (AF)、机械瓣膜置换术和其他凝血障碍（例如抗磷脂抗体综合征、V 因子 Leiden）等疾病中，使用抗凝逆转药物。
因此，患病率不断增加预计未来几年中风的发生将对抗凝逆转药物产生巨大需求，预计这将进一步推动抗凝逆转药物市场的发展。
南美洲和中美洲的抗凝逆转药物市场预计将从2019年为2980万美元，到2027年为6310万美元；预计 2019 年至 2027 年复合年增长率为 10.5%。抗凝逆转药物市场的各个参与者正在开发和推出新产品，以扩大其地理覆盖范围和产能，以满足大量客户的需求。 2018年4月，领先制药公司勃林格殷格翰公司Pradaxa（达比加群酯甲磺酸盐）的特异性逆转剂Praxbind（idarucizumab）获得美国食品药品监督管理局（FDA）全面批准。同样，2018 年 5 月，Portola Pharmaceuticals 获得 FDA 批准，用于因大出血而快速逆转抗凝治疗。新产品的此类开发和批准可能有利于市场增长。
从产品来看，凝血酶原复合物浓缩物细分市场在2019年中南美洲抗凝逆转药物市场中占据最大份额。从分销渠道来看，2019年医院药房在抗凝逆转药市场中占有较大份额。
准备这份关于南美洲和中美洲抗凝逆转药物市场的报告时提到的一些主要一手和二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有勃林格殷格翰国际有限公司
按产品
作者分销渠道
按国家/地区
Strategic insights for South and Central America Anticoagulant Reversal Drug involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 29.8 Million |
| Market Size by 2027 | US$ 63.1 Million |
| Global CAGR (2019 - 2027) | 10.5% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 南美洲和中美洲
|
| Market leaders and key company profiles |
The regional scope of South and Central America Anticoagulant Reversal Drug refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The List of Companies - South and Central America Anticoagulant Reversal Drug Market
The South and Central America Anticoagulant Reversal Drug Market is valued at US$ 29.8 Million in 2019, it is projected to reach US$ 63.1 Million by 2027.
As per our report South and Central America Anticoagulant Reversal Drug Market, the market size is valued at US$ 29.8 Million in 2019, projecting it to reach US$ 63.1 Million by 2027. This translates to a CAGR of approximately 10.5% during the forecast period.
The South and Central America Anticoagulant Reversal Drug Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Anticoagulant Reversal Drug Market report:
The South and Central America Anticoagulant Reversal Drug Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Anticoagulant Reversal Drug Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Anticoagulant Reversal Drug Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Anticoagulant Reversal Drug Market
